Why BONESUPPORT stock moves
Bonesupport fell clearly yesterday without a company-news explanation.
Written after the close on ·
Why today
16,307 news analyzed todayBonesupport fell clearly yesterday without a company-news explanation.
Over the same session, OMX Stockholm 30 also fell clearly, so the stock moved roughly in line with the market.
Over the last five trading days, Bonesupport fell slightly while the market was roughly flat.
The stock stayed well above its mid-February low, and its own trading was around its usual level.
The buy-back programme announced yesterday is background only, since routine buy-backs do not explain moves.
Today's move of −2.02% was 1.4 times a normal day's 1.5%. OMX Stockholm 30 moved −1.01% on the same day.
BONESUPPORT −2.02%OMX Stockholm 30 −1.01%A little weaker than the market
What analysts expect, and how often they have been right
Analysts’ estimates for BONESUPPORT.
BONESUPPORT earned more than expected in 3 out of 6 reports.
For comparison, about 46% of reports from Nordic companies beat the estimate in the last three years.
The share moved in the same direction as the earnings surprise in 4 out of 6 reports with a measured move, against about 63% of reports from Nordic companies.
Ratings
Price targets
Latest price 320.60 SEK
Earnings against expectations, and the share’s reaction
Expected EPSAbove estimateBelow estimateAs expectedSEK
Next reported quarter: expected earnings per share of 1.57 SEK (February 16). For the current fiscal year, expected earnings per share changed from 4.79 SEK three months ago to 5.22 SEK now. 2026 estimate: 5.22 SEK. 2027 estimate: 8.08 SEK. One analyst made the estimate for the quarter. People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor. October 29: Sell about 6.3 m SEK. August 28: Buy about 39 thousand SEK. August 26: Buy about 7 thousand SEK. July 20: Buy about 390 thousand SEK. July 17: Buy about 790 thousand SEK.
Has the share price followed the business?
Price and earnings moved in the same direction: 1 out of 3 years. Across Nordic companies, that happens in about 60% of years. In 2025, the price changed −51% and earnings per share +6%.
Revenue, profit and market cap
RevenueProfitMarket capHatched bars: analysts’ estimates.bn SEK
Assets, liabilities and market cap
AssetsLiabilitiesMarket capbn SEK
Price and earnings moved in the same direction: 1 out of 3 years.Market cap (Now): 20.9 bn SEKRevenue 2025: 1.2 bn SEK
What the key figures say about BONESUPPORT
The figures connect what BONESUPPORT earns with what investors pay.
The line shows the share price in the same year, on its own scale. Hatched bars: analysts’ estimates.
Profit divided by the number of shares. Each share represents this much of the earnings.
2022–2025: -1.06 SEK–3.74 SEK. Peers: AddLife 5.27 SEK, DENTSPLY SIRONA -$0.61, Dynavox Group 2.58 SEK. 2026 estimate: 5.22 SEK (4.84 SEK–5.70 SEK). 2027 estimate: 8.08 SEK (7.30 SEK–8.60 SEK).
What the company sold during the year.
2022–2025: 329 m SEK–1.2 bn SEK. Peers: AddLife 10.7 bn SEK, DENTSPLY SIRONA $3.6B, Dynavox Group 2.6 bn SEK. 2026 estimate: 1.5 bn SEK (1.5 bn SEK–1.5 bn SEK). 2027 estimate: 2.0 bn SEK (1.9 bn SEK–2.1 bn SEK).
The percentage of revenue left after the costs of running the business.
2022–2025: −20.6%–23.6%. Peers: AddLife 10.1%, DENTSPLY SIRONA 5.1%, Dynavox Group 14.7%.
Profit as a percentage of shareholders’ money in the company.
2022–2025: −25.3%–44.9%. Peers: AddLife 11.5%, DENTSPLY SIRONA −8.6%, Dynavox Group 40.4%.
The price investors pay for each unit of annual earnings per share. Not shown for a loss.
2022–2025: 50.3–192.4. Peers: AddLife 34.9, Dynavox Group 27.4. 2026 estimate: 61.4. 2027 estimate: 39.7.
What investors pay for each unit the company sells.
2022–2025: 10.54–28.34. Peers: AddLife 2.10, DENTSPLY SIRONA 0.53, Dynavox Group 2.87. 2026 estimate: 13.72. 2027 estimate: 10.34.
Net debt divided by operating earnings before depreciation and amortisation.
2022–2025: -5.18–-1.14. Peers: AddLife 3.02, DENTSPLY SIRONA 4.17, Dynavox Group 1.58.
More key figures
Market cap divided by shareholders’ equity, what remains after liabilities.
2022–2025: 14.28–35.02. Peers: AddLife 3.77, DENTSPLY SIRONA 1.38, Dynavox Group 9.19.
Market cap plus net debt, divided by operating earnings. This includes debt.
2022–2025: 59.2–641.1.
Cash left after investments, divided by the number of shares.
2022–2025: -0.78 SEK–3.28 SEK. Peers: AddLife 11.43 SEK, DENTSPLY SIRONA $0.72, Dynavox Group 2.18 SEK.
The percentage of assets financed by shareholders’ equity.
2022–2025: 72.3%–83.7%.
What to watch next, and why
The earnings report shows how BONESUPPORT's revenue and profit have changed.
- Earnings report
The earnings report shows how BONESUPPORT's revenue and profit have changed.
Add to calendar
More about BONESUPPORT
Insider trades
People on the board and in management must report their trades in the share to Finansinspektionen, Sweden's financial supervisor.
- Michael Diefenbeck, senior executiveSellabout 6.3 m SEK
- Annelie Aava Vikner, senior executiveBuyabout 39 thousand SEK
- Christine Elizabeth Rankin, board memberBuyabout 7 thousand SEK
- Torbjörn Sköld, CEOBuyabout 390 thousand SEK
- Björn Odlander, board memberBuyabout 790 thousand SEK
Earnings report
Next report: · Add to calendar · Google Calendar
On its last 15 report days BONESUPPORT usually moved about 5.1%. On a normal day it moves 1.5%.
+24.34% Why? −5.83% −1.17% +3.65%
10,000 SEK in BONESUPPORT bought on June 21, 2017 is worth 100,000 SEK today, with dividends reinvested.
What would 10,000 SEK in BONESUPPORT be worth today? →
What would 10,000 SEK in BONESUPPORT be worth today?
100,000 SEK
with dividends reinvested, bought on June 21, 2017.
At worst it was worth 2,900 SEK (June 12, 2018).
The five biggest days of the journey
· −49.3% · the whole market fell 0.2% the same day
· +48.9% · the whole market fell 1.2% the same day
· +27.8% · the whole market rose 0.3% the same day
· +24.3% · the whole market fell 2.5% the same day · report day · Why?
· +20.8% · the whole market fell 0.4% the same day · report day
Earlier days
−1.35% market −0.11% BONESUPPORT fell slightly over the week while the OMX Stockholm 30 was roughly flat. Read →
BONESUPPORT fell slightly over the week while the OMX Stockholm 30 was roughly flat.
The company announced a new buy-back programme of up to SEK 100 million on Thursday 5 November, running from 9 November 2026 to 26 February 2027, which was a company event in the week.
Its previous buy-back had just finished on 30 October, and the stock stayed well above its lowest close of the past year.
Next, the company reports earnings on Tuesday 16 February 2027.
+3.87% market −0.32% BONESUPPORT rose after its new share buyback programme was announced. Read →
BONESUPPORT rose after its new share buyback programme was announced.
It rose sharply while OMX Stockholm 30 fell slightly, so it moved against the market.
The company said it would buy back up to SEK 100 million of its shares, starting no earlier than 9 November.
The shares have risen slightly over the last five trading days, moving more than the market, which also rose slightly.
A new buyback can support a share price, but the reason for the rise is not fully proven.
−4.25% market +0.48% Bonesupport fell sharply, against a rising market. Read →
Bonesupport fell sharply, against a rising market.
Over the last five trading days it fell sharply while OMX Stockholm 30 rose clearly, a big move for the stock.
No company news explains the last session's fall, while the market rose slightly.
The latest close sits well below the late-October high but far above the mid-February low.
A senior executive sold about 20 thousand shares for about 6.3 million SEK on October 29, a sale that may have many reasons.
−2.29% market +3.01% BONESUPPORT fell slightly over the week, while OMX Stockholm 30 rose clearly, so the stock moved against the market. Read →
BONESUPPORT fell slightly over the week, while OMX Stockholm 30 rose clearly, so the stock moved against the market.
The move was ordinary in size for the stock.
Its third-quarter results, released on 22 October, beat expectations, but that news came before this week.
Senior executive Michael Diefenbeck sold about 20,000 shares for roughly SEK 6.3 million on 29 October.
−4.72% market +0.96% BONESUPPORT fell, while OMX Stockholm 30 rose clearly. Read →
BONESUPPORT fell, while OMX Stockholm 30 rose clearly.
No company news from that session explains the drop.
Over the last five trading days the stock rose very sharply while the market was roughly flat, a move about six times a normal five-day stretch.
Its latest quarterly report came out last Thursday, before the last session, showing net sales up 39 percent.
That report was the main company news in the week, but it does not explain a drop in the last session.
+4.00% market +0.41% Bonesupport rose sharply as the market fell, after strong third-quarter results. Read →
Bonesupport rose sharply as the market fell, after strong third-quarter results.
Over the last five trading days, BONESUPPORT rose very sharply while OMX Stockholm 30 fell sharply, a very big move for the stock.
In the last session, the stock rose more than the market, which edged up slightly.
Analysts Nordea and SEB both raised their price targets, the share price they see as fair, and kept their buy ratings.
+31.46% market −3.67% BONESUPPORT rose very sharply over the last five trading days, moving against a market that fell sharply. Read →
BONESUPPORT rose very sharply over the last five trading days, moving against a market that fell sharply.
The main driver was its strong third-quarter report, published yesterday, with sales up 39 percent and an operating profit (EBIT, earnings before interest and tax) well above expectations.
Analysts reacted positively, with SEB raising its price target, the share price it sees as fair, and reiterating its buy rating.
Over the same days the market fell, so the company's results likely drove the gain.
+24.34% market −2.51% Bonesupport rose very sharply, against a falling market. Read →
Bonesupport rose very sharply, against a falling market.
The likely driver was its third-quarter report, published that day, which beat expectations.
Sales grew 39 percent and operating profit rose sharply, with the US segment growing 40 percent.
Trading volume was well above its usual level, and the move was about 14 times a normal day for the stock.
Over the last five trading days the shares also rose very sharply while OMX Stockholm 30 fell clearly.
Learn more · Why do stocks go up and down?